Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1678
    +0.0021 (+0.18%)
     
  • GBP/USD

    1.2493
    -0.0018 (-0.14%)
     
  • Bitcoin GBP

    51,166.93
    -738.51 (-1.42%)
     
  • CMC Crypto 200

    1,332.32
    -64.22 (-4.44%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.64
    +0.07 (+0.08%)
     
  • GOLD FUTURES

    2,348.80
    +6.30 (+0.27%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Global Clinical Trial Biorepository & Archiving Solutions Market (2021 to 2028) - Size, Share & Trends Analysis Report

Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The "Clinical Trial Biorepository & Archiving Solutions Market Size, Share & Trends Analysis Report By Service (Biorepository Services, Archiving Solution Services), By Product (Clinical, Preclinical), By Phase, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global clinical trial biorepository and archiving solutions market size is expected to reach USD 6.0 billion by 2028, according to a new report by the publisher. It is expected to expand at a CAGR of 8.2% from 2021 to 2028. This is largely due to the increasing importance of biological sample management in clinical trials and the desire to streamline the collection and reporting of data.

Biorepositories have entered the Big Data era, which requires new IT technologies, artificial intelligence (AI) techniques, and machine learning and deep learning tools and algorithms. These features help to the paradigm shift toward data-driven science by higher-quality biobanking data. Cloud storage and other new data storage technologies help to solve the problem of limited local storage capacity.

New IT solutions such as the sample/data negotiator and locator, which are part of the BBMRI-ERIC infrastructure, make it easier to discover samples and data that meet specific criteria. This new level of biobanking activity contributes to basic research, translational research, and therapy of a wide range of human disorders, including cancer, CVD rare diseases, diabetes, and neurodegenerative diseases.

Besides, the COVID-19 pandemic has created opportunities for local players. To enhance their foothold in the market, key companies are adopting various plans and policies to gain a greater market share. The important step that key players can incorporate is to partner with relevant third-party vendors. It can be achieved by proper communication and adjustments in the frequency and volume of clinical trial biorepository and archiving solutions.

Clinical Trial Biorepository & Archiving Solutions Market Report Highlights

  • By service, biorepository services dominated the market with a revenue share of 67.2% in 2020. This can be attributed to the rise in R&D of advanced therapies such as personalized medicine and the requirement of high-quality biorepository practices for the collection, processing, testing, and storage of samples

  • In terms of phase, the phase III segment dominated the market with a revenue share of 52.1% in 2020

  • Based on product, clinical products held the largest share of 63.1% in 2020. This can be attributed to the fact that most clinical trial protocols depend largely on the analysis of biological specimens to meet the study endpoints

  • Asia Pacific is anticipated to register the fastest growth rate of 15.3% over the forecast period. The shift of clinical trial sites from Western regions, such as Europe and North America, to Asia Pacific is a major driver for the regional market

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Biorepository & Archiving Solutions Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Growing number of pharmaceutical and biotechnology companies
3.2.1.2 Growing disease variation and prevalence
3.2.1.3 Increasing R&D investments
3.2.1.4 Growth in CRO Market
3.2.2 Market Restraint Analysis
3.2.2.1 Regulations in new drug development
3.2.2.2 Rising cost of clinical trials
3.3 Penetration & Growth Prospect Mapping
3.4 COVID-19 Impact on the Market
3.5 Major Deals and Strategic Alliances Analysis
3.6 Clinical Trial Biorepository & Archiving Solutions: Market Analysis Tools
3.6.1 Industry Analysis - Porter's
3.6.2 PESTEL Analysis

Chapter 4 Clinical Trial Biorepository & Archiving Solutions Market: Service Segment Analysis
4.1 Clinical Trial Biorepository & Archiving Solutions Market: Service Market Share Analysis, 2020 & 2028
4.2 Biorepository Services
4.2.1 Biorepository Services Market, 2016 - 2028 (USD Million)
4.3 Archiving Solution Services
4.3.1 Archiving Solution Services Market, 2016 - 2028 (USD Million)

Chapter 5 Clinical Trial Biorepository & Archiving Solutions Market: Product Segment Analysis
5.1 Clinical Trial Biorepository & Archiving Solutions Market: Product Market Share Analysis, 2020 & 2028
5.2 Preclinical Products
5.2.1 Preclinical Products Market, 2016 - 2028 (USD Million)
5.3 Clinical Products
5.3.1 Clinical Products Market, 2016 - 2028 (USD Million)

Chapter 6 Clinical Trial Biorepository & Archiving Solutions Market: Phase Segment Analysis
6.1 Clinical Trial Biorepository & Archiving Solutions: Phase Market Share Analysis, 2020 & 2028
6.2 Phase I
6.2.1 Phase I Market, 2016 - 2028 (USD Million)
6.3 Phase II
6.3.1 Phase II Market, 2016 - 2028 (USD Million)
6.4 Phase III
6.4.1 Phase III Market, 2016 - 2028 (USD Million)
6.5 Phase IV
6.5.1 Phase IV Market, 2016 - 2028 (USD Million)

Chapter 7 Clinical Trial Biorepository & Archiving Solutions Market: Regional Analysis

Chapter 8 Company Profiles
8.1 Brooks Life Science
8.1.1 Company Overview
8.1.2 Service Benchmarking
8.1.3 Financial Performance
8.1.4 Strategic Initiatives
8.2 Patheon
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Service Benchmarking
8.2.4 Strategic Initiatives
8.3 Precision For Medicine, Inc.
8.3.1 Company Overview
8.3.2 Service Benchmarking
8.3.3 Strategic Initiatives
8.4 Medpace
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Service Benchmarking
8.5 LabCorp Drug Development
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Service Benchmarking
8.6 ATCC
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Service Benchmarking
8.7 Q2 Solutions
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Service Benchmarking
8.7.4 Strategic Initiatives
8.8 Labconnect
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Service Benchmarking
8.9 Charles River Laboratories
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Service Benchmarking
8.9.4 Strategic Initiatives
8.9.5 Strategic Initiatives
8.10 Cell&Co
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Service Benchmarking
8.10.4 Strategic Initiatives
8.10.5 Strategic Initiatives

ADVERTISEMENT

For more information about this report visit https://www.researchandmarkets.com/r/9rjedt

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900